Research
Hormonal
Orforglipron, an oral non-peptide GLP-1 receptor agonist, produces significant, dose-dependent weight loss (8.5–8.8%) in adults with obesity at doses of 24–36 mg/day, with gastrointestinal side effects being the primary limiting factor.
Take orforglipron once daily. Start at a low dose (6-9 mg) and increase to 12 mg, then to 24-36 mg as tolerated. Expect 8-9% body weight loss over 6 months. Manage nausea by titrating slowly.
GoodSupportsHIGH confidence
Orforglipron at 24–45 mg/day doses is an effective weight loss medication. The efficacy versus side effect profile suggests that 24–36 mg/day is the most optimal dose for orforglipron as an anti‐obesity medicine.
Why this rating
Meta-analysis of 3 RCTs (n=774) with low risk of bias, though heterogeneity was noted.
Source
Orforglipron, a novel non‐peptide oral daily glucagon‐like peptide‐1 receptor agonist as an anti‐obesity medicine: A systematic review and meta‐analysis
Deep Dutta et al. · Obesity Science & Practice · 2024
DOI 10.1002/osp4.743
Meta-analysis · 3 studiesCited 24×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →